Tesamorelin
Explore tesamorelin, visceral fat research and the difference between its specific approved use and general weight-loss claims.
Have questions? Start with a free consultation.
No deposit. Our Gilbert team will contact you within one business day.
Understand the topic before choosing a treatment
Tesamorelin is a growth-hormone-releasing hormone analog. An FDA-approved product has a specific role in excess abdominal fat associated with HIV lipodystrophy; that does not make it a general weight-loss medication.
Waist changes, body weight and physical function are different goals. A consultation can clarify which concern matters to you and what evaluation fits it.
This is an educational guide. It does not establish product availability or that this option is suitable for you.
How it works—and what that tells us
Tesamorelin stimulates pituitary growth hormone release and downstream IGF-1 activity. Acting through that signaling system does not eliminate risks from increased growth hormone activity.
A mechanism explains how something may act.
Clinical studies test benefits and harms in specific people.
Your goals and health history shape the next step.
What the evidence shows
Product- and indication-specific clinical evidence
The EGRIFTA WR label supports its use for excess abdominal fat in adults with HIV and lipodystrophy. It specifically excludes general weight-loss management; long-term cardiovascular safety has not been established.
What it does not establish
- Evidence for an approved product cannot simply be transferred to a compounded formulation.
- A change in visceral fat is not proof of longer life, improved cognition or benefit for every person with abdominal weight.
Safety questions worth discussing
- The label contraindicates use in pregnancy, active malignancy and certain pituitary-axis disorders.
- Elevated IGF-1, glucose intolerance, fluid retention and hypersensitivity require clinician attention.
Bring your goals to the conversation
You can start with what you want to understand or improve. A consultation can help you assess the research and discuss other approaches; it does not commit you to a particular treatment.
- Is my concern weight, waist size, metabolic risk or loss of strength?
- What evidence applies to my health history rather than a different study population?
- Which alternatives and monitoring requirements should we discuss?
Common questions about Tesamorelin
Is tesamorelin FDA-approved for ordinary weight loss?
No. Its approved product has a specific HIV-lipodystrophy indication. The label says it is not indicated for weight-loss management.
Does stimulating my own growth hormone make it risk-free?
No. The downstream effects still matter, including blood sugar, IGF-1 and fluid retention.
Should I add it to a weight-loss medication?
That is not an automatic next step. Review your diagnosis, nutrition, strength, response to current care and evidence for any proposed combination with the clinician.
Sources and further reading
- EGRIFTA WR prescribing information
U.S. Food and Drug Administration · 2025 - Understanding the risks of compounded drugs
U.S. Food and Drug Administration · Current guidance
The cited sources describe particular products, study populations or research questions. They are not endorsements of a LifeSpann treatment. Meet our team.
Start with your goals. The consultation is free.
Free consultation · No deposit
Talk through what you want to achieve, the evidence, and the options worth considering. You do not need to choose a peptide or commit to treatment.
Our front desk will contact you within one business day to answer questions and schedule your consultation.
Prefer to call? (480) 351-7151